- GeneDx Reports First Quarter 2024 Financial Results and Business Highlights
- GeneDx Announces Partnership with Komodo Health to Expand Access to World’s Largest Rare Disease Dataset
- GeneDx to Report First Quarter 2024 Financial Results on Monday, April 29, 2024
- GeneDx to Present Data at the 2024 American College of Medical Genetics (ACMG) Annual Meeting Demonstrating Clinical Superiority of its Exome, Paving the Way for the Future of Genomics
- GeneDx to Participate in 44th Annual Cowen Health Care Conference
- GeneDx Reports Fourth Quarter and Full Year 2023 Financial Results and Issues Guidance for Full Year 2024
- GeneDx to Report Fourth Quarter 2023 Financial Results on Tuesday, February 20, 2024
- GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- GeneDx Announces Preliminary 2023 Financial Results
- GeneDx Presents New Data at the American Epilepsy Society Annual Meeting Demonstrating That Exome Sequencing Outperforms Multi-Gene Panels for Patients with Epilepsy
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 23.85 |
---|---|
High | 24.40 |
Low | 22.27 |
Bid | 22.41 |
Offer | 24.39 |
Previous close | 24.02 |
Average volume | 683.62k |
---|---|
Shares outstanding | 26.15m |
Free float | 17.96m |
P/E (TTM) | -- |
Market cap | 585.52m USD |
EPS (TTM) | -5.25 USD |
Data delayed at least 15 minutes, as of May 17 2024 21:00 BST.
More ▼